419 related articles for article (PubMed ID: 559720)
41. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.
Whaley K; Thompson RA
Immunology; 1978 Dec; 35(6):1045-9. PubMed ID: 83964
[TBL] [Abstract][Full Text] [Related]
42. The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system.
Brown EJ; Joiner KA; Gaither TA; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):409-15. PubMed ID: 6223077
[TBL] [Abstract][Full Text] [Related]
43. Reaction mechanisms of beta1H globulin.
Nagaki K; Iida K; Okubo M; Inai S
Int Arch Allergy Appl Immunol; 1978; 57(3):221-32. PubMed ID: 77846
[TBL] [Abstract][Full Text] [Related]
44. Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins.
Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1978 Dec; 148(6):1722-7. PubMed ID: 722244
[TBL] [Abstract][Full Text] [Related]
45. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
Pangburn MK; Müller-Eberhard HJ
Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
[TBL] [Abstract][Full Text] [Related]
46. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
48. The mechanism of activation of the alternative pathway of complement by cell-bound C4b.
Farries TC; Steuer KL; Atkinson JP
Mol Immunol; 1990 Nov; 27(11):1155-61. PubMed ID: 2247091
[TBL] [Abstract][Full Text] [Related]
49. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement.
Fischer E; Kazatchkine MD
J Immunol; 1983 Jun; 130(6):2821-4. PubMed ID: 6222117
[TBL] [Abstract][Full Text] [Related]
50. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte.
Fearon DT
J Exp Med; 1980 Jul; 152(1):20-30. PubMed ID: 6967510
[TBL] [Abstract][Full Text] [Related]
51. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
53. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
54. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
55. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
Melamed J; Medicus RG; Arnaout MA; Colten HR
J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
[TBL] [Abstract][Full Text] [Related]
56. Action of the C3b-inactivator on the cell-bound C3b.
Law SK; Fearon DT; Levine RP
J Immunol; 1979 Mar; 122(3):759-65. PubMed ID: 448074
[TBL] [Abstract][Full Text] [Related]
57. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800
[TBL] [Abstract][Full Text] [Related]
58. Formation of high affinity C5 convertase of the classical pathway of complement.
Rawal N; Pangburn MK
J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
[TBL] [Abstract][Full Text] [Related]
59. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
Pryzdial EL; Isenman DE
J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
[TBL] [Abstract][Full Text] [Related]
60. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
